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Numerous severe neurodegenerative and neuromus-
cular disorders, characterized biochemically by strong
perturbations in energy metabolism, are correlated
with single point mutations in mitochondrial genes cod-
ing for transfer RNAs. Initial comparative proteomics
performed on wild-type and Myoclonic Epilepsy and
Ragged Red Fibers (MERRF) mitochondria from sibling
human cybrid cell lines revealed the potential of this
approach. Here a quantitative analysis of several hun-
dred silver-stained spots separated by two-dimensional
gel electrophoresis was performed in the specific case of
a couple of mitochondria, containing or not mutation
A8344G in the gene for mitochondrial tRNALys, corre-
lated with MERRF syndrome. Computer-assisted analy-
sis allowed us to detect 38 spots with significant quan-
titative variations, of which 20 could be assigned by
mass spectrometry. These include nuclear encoded pro-
teins located in mitochondria such as respiratory chain
subunits, metabolic enzymes, a protein of the mitochon-
drial translation machinery, and cytosolic contami-
nants. Furthermore, Western blotting combined with
mass spectrometry revealed the occurrence of numer-
ous isoforms of pyruvate dehydrogenase subunits, with
subtle changes in post-translational modifications. This
comparative proteomic approach gives the first insight
for nuclear encoded proteins that undergo the largest
quantitative changes, and pinpoints new potential mo-
lecular partners involved in the cascade of events that
connect genotype to phenotype.
Mitochondria are the center of numerous metabolic functions
of primary importance to the cell. They are responsible for the
major ATP synthesis pathway and thus deliver energy through
the activity of respiratory chain complexes and ATP synthase,
all located in the inner mitochondrial (mt)1 membrane. Mito-
chondria also contain major catabolic pathways including the
citric acid cycle, fatty acid oxidation, part of the urea cycle, and
a number of biosynthetic pathways such as those for heme,
ubiquinol, and cardiolipin (1). To fulfill these functions, mito-
chondria produce a subset of 13 proteins by translation of their
own genes and import a large number of proteins encoded by
the nuclear genome (estimated 400–2000), translated within
the cytosol. Among these are numerous proteins allowing
maintenance and expression of the mt genome (replicase, tran-
scription factors, and translation proteins). Thus, mt functions
depend on well coordinated cross-talks between mt and nuclear
genomes, allowing for a controlled balance between mitochon-
dria encoded and nuclear encoded proteins and associated en-
zymatic activities.
Mt genomes are very sensitive to mutations (2–4). In the
case of human, as many as 150 point mutations have been
correlated already with various neuromuscular and neurode-
generative disorders (5–8). tRNA genes, which correspond only
to about 10% of the mt genome, are particularly sensitive
because they host about 80 of the known pathogenesis-associ-
ated mutations. Genotype/phenotype relationships for these
disorders are complex because one mutation can be related to
several disorders, and conversely a same disorder can arise
from several different mutations. Due to the central role of
tRNAs in protein synthesis (9), defects in structure/function
relationships of mutant tRNAs have been sought (e.g. reviewed
in Refs. 5, 6, 8, 10–13). The rate of synthesis of the 13 mito-
chondria-encoded proteins is decreased, and tRNA maturation,
stability, post-transcriptional modification, structure, amino-
acylation, and/or codon reading properties can be affected.
However, depending on the specific case studied, distinct re-
sults were observed, confirming a complex relationship be-
tween genotypes and phenotypes and suggesting the contribu-
tion of additional factors to the expression of the disease (14).
Furthermore, in some instances no defect in protein synthesis
was observed, a discovery in support of mediators outside mt
translation (15).
Comparative proteomics is a powerful approach to investi-
gate quantitative variations in several hundred proteins at
once (16, 17). Its application to human mitochondria would
enlarge insight into unexpected consequences of a single point
mutation in a tRNA gene on the global mt protein content.
Such an approach particularly enables the analysis of the fate
of nuclear encoded proteins located in mitochondria. Investiga-
tion of human mt tRNA gene mutations suffers so far from the
absence of animal model systems (e.g. Refs. 18–20). An initial
proteomic study performed on mitochondria from sibling cybrid
cell lines, in the presence or absence of a single point mutation
in one mt tRNA gene, has already proven the feasibility and the
potential impact of such an approach for the investigation of mt
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tRNA disorders (21). In mitochondria carrying tRNALys gene
mutation A8344G, associated with Myoclonic Epilepsy and
Ragged Red Fibers (MERRF syndrome (22)), a large decrease
in the steady-state levels of two nuclear encoded subunits of
cytochrome c oxidase, a respiratory chain complex, was identi-
fied upon simple visual comparison of two-dimensional PAGE
(isoelectrofocusing/SDS-PAGE) followed by mass spectrometric
assignment. Here the cybrid model system was further ex-
plored by a detailed computer-assisted quantitative compari-
son of over 800 spots obtained from wild-type and mutation
A8344G-carrying mitochondria. This first large scale quantita-
tive analysis of the protein profile of mitochondria representa-
tive of a tRNA disorder, using cybrid cell lines as a model
system, revealed that in addition to the 13 mitochondria en-
coded proteins, all known to be affected, several nuclear en-
coded proteins of mt location undergo quantitative and/or qual-
itative changes.
The proteomic approach enlarges the view of the status of a
disease-carrying cell, highlighting new molecular species rele-
vant to perturbations within the whole cell, beyond the conse-
quences of the primary molecular impact of a mutation on the
tRNA structure/function relationship in translation. Under-
standing how each of these species affects the cell will shed new
light on the genotype/phenotype relationships of mt disorders.
Although some of the affected proteins may contribute to the
expression of the disease, others may be compensating.
EXPERIMENTAL PROCEDURES
Cell Cultures
Human osteosarcoma-derived cybrid cell lines R2-1A and R1C3 were
a kind gift of A. Chomyn and G. Attardi (California Institute of Tech-
nology, Pasadena). Cell line R2-1A carried the wild-type mt tRNALys
gene in homoplasmic form, and cell line R1C3, associated with MERRF
disease, carries an A to G transition at position 8344 in this gene in
homoplasmic form (23). Cell lines were grown in Dulbecco’s modified
Eagle’s medium with 10% fetal calf serum, 100 units/ml penicillin, 100
g/ml streptomycin, and 100 g/ml bromodeoxyuridine at 37 °C in the
presence of 5% CO2 and 85% humidity. R2-1A cells were seeded at a
density of 2 105 cells/10 ml of medium/10-cm diameter Petri dish, and
R1C3 cells were seeded at a density of 5  105 cells/10 ml/10 cm
diameter. Upon reaching confluence, cells were passed (not more than
4 or 5 times), and 50–100 dishes, containing 4  106 cells each
(confluent culture), were harvested for mitochondria isolation. Stability
of the cell lines was verified in regard to the tRNALys and tRNALeu(UUR)
gene sequences, which were found to be unchanged over the period of
experimentation.
Isolation of Mitochondria
Mitochondria were purified according to established procedures (21)
with slight modifications. Briefly, cybrid cells were detached by
trypsinization, centrifuged, and washed twice with cell dissociation
buffer (25 mM Tris-HCl, pH 7.4, 135 mM NaCl, 5 mM KCl, 0.5 mM
NaH2PO4). Cell pellets were resuspended in 210 mM mannitol, 70 mM
sucrose, 5 mM Hepes, pH 7.2, and 2 mM EDTA (isolation buffer). Cyto-
solic membranes were permeabilized by a short digitonin treatment (1
min on ice, 0.04 to 0.1 mg/100 mg of total protein as measured by the
Bradford technique). Permeabilization efficiency was monitored under
the microscope by trypan blue staining. Cells were centrifuged, sus-
pended in the same buffer without digitonin, and broken in a Potter-
Elvehjem homogenizer with a rotating pestle up to80% cell breakage.
The homogenate was centrifuged at 900  g for 5 min at 4 °C to remove
nuclei and large debris. The supernatants were recovered and centri-
fuged again at 900  g for 5 min at 4 °C. This centrifugation step was
repeated until the pellet became invisible (about 7–8 times). The final
supernatant was centrifuged for 20 min at 10,000  g to collect mito-
chondria. Mitochondrial pellets were washed once, then resuspended in
a small volume of isolation buffer, and stored at80 °C. Protein content
was estimated by the Bradford method used directly with mitochondria.
Mitochondria per cell, estimated by citrate synthase activity (units per
mg of total cellular protein content), was found to be similar in both cell
lines (125 milliunits/mg).
Two-dimensional PAGE
For analytical gels, samples consisted of 50–150 g of mt protein in
100 l of isolation buffer. For preparative gels, samples consisted of 500
g of protein. Mitochondria were solubilized by addition of 400 l of
“lysis buffer” containing 9 M urea, 2.5 M thiourea, 5% CHAPS, 12.5 mM
dithiothreitol (DTT), and 0.5% carrier ampholytes (pH 3–10) to the
100-l mt suspension. The mixture was sonicated for 3 min before
application to the strip.
Samples were deposited on linearly immobilized 17 cm long, pH 5–8
IPG strips (Bio-Rad), followed by passive overnight rehydration at
22 °C. Strips were prevented from dehydration and oxidation by cover-
ing with mineral oil (Bio-Rad). Isoelectrofocusing was performed for a
total of 53,600 V-h at 22 °C (Bio-Rad, Protean IEF Cell) by application
of 300 V for 2 h (to remove salt), 1500 V for 2 h (fast increasing slope),
3000 V for 16 h (focusing), and 500 V for 4 h (stabilization). Strips were
equilibrated 2 times for 15 min in 0.125 M Tris-HCl, pH 7.7, 6 M urea,
30% glycerol, and 2.5% SDS, first with 65 mM DTT (reduction step), and
finally with 216 mM iodoacetamide (alkylation step).
The second dimension was run after fixing each strip with 1% low
melting point bromphenol blue containing agarose solution, on top of a
20  20-cm 10% acrylamide gel, cast in 0.2 M Tris-HCl, pH 8.1. Protein
samples were electrophoresed using Tris taurine (0.05 M Tris, 0.2 M
taurine, 0.1% SDS) as upper buffer (cathode), and Tris glycine (0.05 M
Tris, 0.4 M glycine, 0.1% SDS) as lower buffer (anode) (21). Samples
were electrophoresed at 40 mA/gel until the bromphenol blue reached
the bottom of the gel (about 5 h). This allowed resolution of low molec-
ular mass proteins down to 7 kDa. Proteins from wild-type and MERRF
mitochondria were always run together in the same electrophoresis
tank.
Protein Staining
Silver Staining—Gels loaded with 100–150 g of proteins were
stained according to Ref. 21. Gels were fixed overnight with 5% acetic
acid, 30% ethanol, sensitized with 0.02% sodium thiosulfate for 1 min,
stained with 0.2% AgNO3 in ultrapure water for 90 min, developed in
4% potassium carbonate, 0.25 ml/liter formaldehyde, 0.025% sodium
thiosulfate. Staining reaction was stopped by 4% Tris base (m/v), 2%
acetic acid treatment. Gels were rinsed, scanned (GS-710 Calibrated
Imaging Densitometer, Bio-Rad), and dried. This staining method is
sensitive enough to detect about 800 spots on gels loaded with 100 g of
protein. For gels loaded with 50–70 g of proteins, a more sensitive
silver staining method (PlusOne Kit, Amersham Biosciences) was ap-
plied according to manufacturer’s instructions.
Colloidal Blue (G-250) Staining—Preparative gels loaded with 500
g of proteins were fixed 3 times for 30 min with 30% ethanol, 2%
phosphoric acid. Gels were rinsed 3 times for 20 min with 2% phos-
phoric acid and then equilibrated with a solution containing 2% phos-
phoric acid, 18% ethanol, 15% ammonium sulfate for 30 min. Colloidal
Blue G (Sigma) was added to the equilibration solution at a final
concentration of 0.02%. Gels were stained for 24–36 h, washed with
water to decrease background, and scanned. Finally spots of interest
were excised with caution to avoid keratin contamination and stored at
20 °C until mass spectrometry analysis.
Gel Imaging and Spot Quantification
For quantitative analysis, gels were silver-stained. This method has
a more restricted linear range compared with colloidal blue staining but
requires about 10 times less protein for detection, an important factor
when preparing mitochondria from adherent cell cultures. Comparison
of spot intensities in two independent experiments revealed by either
silver or colloidal blue staining lead to the same quantitative results
except in the case of fairly dark (still not saturated) spots. In this latest
case, intensity differences for a same spot in wild-type and mutant
mitochondria were greater in blue gels. Thus, silver staining may tend
to underestimate some of the spot intensity increases in two-dimen-
sional maps.
Quantitative, computer-assisted gel analysis was carried out with
the help of PD-QUEST software (Bio-Rad). Each scanned image was
converted to gray scale pixel values by the program. All spot values
were normalized according to total density in the gel image, which
allows the precise comparison of gels even with different (high and low)
backgrounds. Eleven gel couples (wild-type and MERRF mitochondria),
run in parallel, were analyzed. After automatic detection, spots result-
ing from non-protein sources (e.g. dust, silver particles, and scratches)
were filtered out. Operator intervention was required to set landmarks
on each gel for accurate cross-gel image matching. This matching pro-
cedure resulted in a “master gel” containing all spot information of both
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gels (spot size, density, quantity in volume (pixel  OD  spot surface),
etc.). Spot volumes were compared across 11 “master” gels for each
matched spot, and data were analyzed under Excel. Ratios of protein
quantities (spot volumes) were established for corresponding spots
(wild-type and mutation carrying sample), and mean values as well as
standard errors were calculated.
Spot Analysis by Mass Spectrometry
Up-regulated spots were analyzed after excision from gels containing
mutated mitochondria, and down-regulated spots were analyzed from
wild-type mitochondria gels.
In-gel Digestion—Reduction was achieved by a 1-h treatment of the
gel spots in 10 mM DTT at 57 °C. Alkylation reaction was performed
using 25 mM iodoacetamide for 45 min at room temperature and pro-
tected from light. Tryptic digestion was performed in 12.5 ng/l trypsin
(Promega, V5111) in 25 mM NH4HCO3 (freshly diluted) at 35 °C over-
night. Gel pieces were centrifuged, and 5 l of 25% H2O, 70% acetoni-
trile, 5% HCOOH were added to extract peptides. For MALDI-MS
analysis, the supernatant volume was reduced under nitrogen flow to 4
l; 1 l of H2O, 5% HCOOH were added, and 0.5 l of the mix were used
for analysis. For nano-LC-MS-MS, the supernatant solvent was com-
pletely evaporated in order to remove all acetonitrile from the sample.
Then 10 l of H2O, 5% HCOOH were added and injected in the high
pressure liquid chromatography system.
MALDI-MS—For MALDI mass spectrometry, mass measurements
were carried out on a Bruker BIFLEX IIITM MALDI-TOF equipped with
the SCOUTTM High Resolution Optics with X-Y multisample probe and
gridless reflector. Internal calibration was performed with tryptic pep-
tides coming from autodigestion of trypsin, with monoisotopic masses at
m/z  842.51, 1045.564, and 2211.105. Monoisotopic peptide masses
were assigned and used for data base searches. These files were then
fed into the search engine MASCOT (Matrix Science, London, UK). The
data were searched against the NCBI non-redundant protein sequence
data base with trypsin plus potentially two missed cleavages. All pro-
teins present in NCBI were taken into account without any pI and
molecular weight restrictions. Some variable modifications were taken
into account, like methionine oxidation, cysteine carbamidomethyla-
tion, and serine, threonine, or tyrosine phosphorylations. Detection of
phosphorylated peptides resulted in matches at 80 Da higher masses/
phosphate group, compared with non-phosphorylated peptides. The
peptide mass error was limited to 50 ppm.
Nano-LC-MS-MS—Nanoscale capillary liquid chromatography-tan-
dem mass spectrometric (LC-MS-MS) analysis of the digested proteins
were performed using a CapLC capillary LC system (Micromass,
Manchester, UK) coupled to a hybrid quadrupole orthogonal accelera-
tion time-of-flight tandem mass spectrometer (Q-TOF II, Micromass).
The LC-MS union was made with a PicoTip (New Objective, Woburn,
MA) fitted on a ZSPRAY (Micromass, Manchester, UK) interface. Chro-
matographic separations were conducted on a reversed phase capillary
column (Pepmap C18, 75 m inner diameter, 15 cm length, LC Pack-
ings) with a 200 nl/min flow. The gradient profile used consisted of a
linear gradient from 95% A (H2O, 0.05% HCOOH) to 45% B (acetoni-
trile, 0.05% HCOOH) over 35 min followed by a linear gradient to 95%
B for 1 min. Mass data acquisitions were piloted by MassLynx software
(Micromass, Manchester, UK) using automatic switching between MS
and MS-MS modes. Mass data collected during a LC-MS/MS analysis
were processed and converted into a .PKL file to be submitted to the
search software MASCOT (Matrix Science, London, UK). Searches were
done with a tolerance on mass measurement of 0.25 Da in MS mode and
0.5 Da in MS/MS mode.
Western Blotting
Mitochondrial proteins derived from four independent prepara-
tions (10 g) were run on one-dimensional 10% SDS-polyacrylamide
gels (10  8 cm) and transferred to Immobilon P membrane (Milli-
pore). After saturation with 5% milk powder in 20 mM Tris-HCl, pH
7.5, 0.5 M NaCl, reaction with specific antibodies (dilution 1:1000)
was performed. The three different antibodies tested were anti-bo-
vine pyruvate dehydrogenase E1 (gift of Dr. G. Lindsay), anti-bovine
mt elongation factor (gift of Dr. L. Spremulli), and anti-human lysyl-
tRNA synthetase (gift of Dr. K. Shiba). Each antibody was used at
1:1000 dilution. Secondary antibody was horseradish peroxidase cou-
pled anti-rabbit IgG (dilution 1:5000), and reaction was revealed by
the ECL method (Amersham Biosciences). After exposure, quantita-
tive comparison of wild-type and mutant samples was performed with
Quantity One software (Bio-Rad). Western blotting was also per-
formed on two-dimensional gels loaded with 50–250 g of mt proteins
and probed with either of the three antibodies. Treatment of Immo-
bilon membrane was as described above.
Pyruvate Dehydrogenase Activity
Total and basal activities were assayed by the release of 14CO2 from
[1-14C]pyruvic acid, as described (24) with minor modifications. Cell
lines were grown on a 6-ml dish until confluent. Each dish was har-
vested in 1 ml of lysis buffer (100 mM KH2PO4, pH 7.4, 2 mM EDTA, 1
mM DTT), frozen in liquid nitrogen, and stored at80 °C. For the assay,
cells were thawed and gently sonicated (4 pulses, microtip 20, 50%).
Three dishes of each cell type were pooled, and the assay was performed
in triplicate. Cells were preincubated for 10 min at 37 °C with 0.04 mM
MgCl2 and 0.04 mM CaCl2 (basal activity) or with 16 mM MgCl2 and 0.4
mM CaCl2 (total activity). They were incubated for 15 min at 37 °C as
described (24). The reaction was stopped with 0.1 ml of 50% trichloro-
acetic acid and left at room temperature for 90 min to allow capture of
CO2.
RESULTS
Model System—The protein content of mitochondria isolated
from sibling cybrid cell lines, homoplasmic either for wild-type
or for the MERRF mutation A8344G in the tRNALys gene, has
been compared. The origin of both cybrid cell lines is an osteo-
sarcoma cell line devoid of mitochondria, fused with enucleated
myoblasts of a MERRF patient carrying mutation A8344G in a
heteroplasmic form (25). Emerging cybrid cells were selected
for the presence (R1C3 cells) or the absence (R2-1A cells) of
mutation A8344G in the tRNALys gene in homoplasmic form. In
consequence, these cell lines have the same nuclear back-
ground and are distinguished only by the presence or absence
of mutation A8344G in their mtDNA. This model system has
already been genetically and biochemically characterized and
used to study MERRF mutation-related biochemical and mo-
lecular events (10, 21, 23, 26, 27). In the absence of transgenic
mice and/or access to significant patient biopsy samples, cybrid
cell lines represent the only valuable model system to evaluate
direct or indirect effects of a human mt tRNA gene mutation at
the cellular level and are thus used here for a comparative
proteomic approach.
A major limitation in establishing mt proteomes resides in
the difficulty of organelle purification and thus in the possible
presence of lysosomal, peroxisomal, and cytosolic proteins in
mt preparations. This is indeed a drawback when searching for
the exact exhaustive protein content within a given organelle,
a situation different from the aim of the present study. Here
the comparative proteomic strategy was applied to highlight
proteins undergoing quantitative changes when comparing
wild-type and MERRF mitochondria. Due to the large amounts
of protein required per analysis and to the low yield of mito-
chondria from adherent cybrid cell growth, purification of mi-
tochondria was limited to differential centrifugations, so that
contaminants on two-dimensional maps were not unexpected.
Two-dimensional PAGE of Total Mitochondrial Proteins and
Quantitative Aspects—Well resolved silver-stained two-dimen-
sional maps of mt proteins were obtained in a reproducible
manner according to procedures established previously (21)
and allowed detection of about 800 spots (Fig. 1). Quantifica-
tion was performed on 11 gel couples to allow for a significant
analysis by comparison of spot intensities, measured as spot
volumes. Normalization of gels (loaded with the same amount
of mt proteins), done either according to the total quantity in
valid spots or to the total density in gel, leads to the same
results and allowed differences linked to experimental proce-
dures (protein loading and staining) to be eliminated so that
only significant variations related to the type of sample (wild-
type or mutant) were considered. For the same spot, intensity
varied on average by 20–40% over the different gels of the
same type (i.e. within all wild-type or all mutant gels). Accord-
ingly, spot intensity variations greater than these values were
Proteomics on MERRF Cybrids24316
 by guest on A
pril 10, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
sought when comparing normalized wild-type and MERRF-
related two-dimensional maps. Change by a factor 2 was cho-
sen as the basis for systematic comparison.
The majority of the spots (about 760) did not show significant
intensity variations between wild-type and mutant gels. Alto-
gether, 38 spots (4.75% of detectable spots) were found to be
affected in intensity, 19 of which decreased and 19 increased.
They are located all over the two-dimensional gels, covering
small as well as large molecular weight domains and all the pI
ranges considered (Fig. 1). Fig. 2, A and B, summarizes quan-
titative variations of these individual spots as an outcome of
the 11 independent experiments. The range of differential spot
intensities between wild-type and MERRF mitochondria varied
from 2.1- to 9-fold, with most spots affected 2–5-fold. The ma-
jority of affected spots had low expression levels, with 27 spots
out of 38 with intensities under 700 pixels, the highest inten-
sity reaching 3700 pixels in both types of samples.
Spot Assignment—Differentially expressed protein spots as
well as a number of non-affected spots were assigned by mass
spectrometric (MS) techniques. Identification (in 2–3 independ-
ent experiments) was mainly done by MALDI-TOF on colloidal
blue-stained gels, based on a minimum of 3 or 4 matching
peptides with a peptide mass tolerance of 50 ppm. A typical
case is shown in Fig. 3. Nano-LC-MS-MS, an approach leading
to the amino acid sequence of a given peptide, was used as a
complementary technique in some instances (Fig. 4). For some
spots, identification was not successful (lack of signal for spots
of low density, recovery of only a few peptides for proteins of
low molecular weight, proteins poor in trypsin cleavage sites,
low efficiency of peptide extraction from gel, etc.).
Table I lists identified spots. Most proteins correspond to
nuclear encoded mt proteins, but some were cytosolic contam-
inants. All proteins of expected mt location appeared at gel
coordinates in the range of molecular weight and pI values of
their mature forms, and no peptides issued from the targeting
signals were detected by MALDI analyses. Differences between
theoretical and experimental pI were accounted for either by
distortions in the pH gradient or by post-translational modifi-
cations of the corresponding protein (see below).
Spots with decreased intensities in MERRF mitochondria as
compared with wild-type mitochondria were assigned princi-
pally as nuclear encoded subunits of respiratory chain com-
plexes, especially from complex IV or cytochrome c oxidase
(COX VIa (spot 41), COX Vb (spot 42), and COX VIb (spot 34))
and complex I or NADH ubiquinone oxidoreductase (subunits
13 (spot 35) and 24 kDa (spot 46) as well as three isoforms
(same molecular weight but slightly different pI values) of the
75-kDa subunit (spots 67, 68, and 69)). Furthermore, mitochon-
drial ornithine aminotransferase (spot 61), a protein involved
in arginine metabolism, underwent a 2.8-fold decrease in in-
tensity, and 2 isoforms of peroxisomal enoyl-CoA hydratase
(spots 50, 51) underwent a 2.1–3.1-fold decrease.
Within spots of increased intensity, 4 have been assigned as
proteins of mt location. They correspond to subunits of the
metabolic enzyme pyruvate dehydrogenase (PDH) subunit E1
(spot 28), an isoform of this protein (spot 31) and subunit E1
(spot 16). Several non-mitochondrial proteins such as cytosolic
translation elongation-factor 1 (spot 30), septin 2 (spot 27),
-actin (spots 13 and 15), guanine nucleotide-binding protein
subunit 3 (spot 13), and lysosomal tripeptidyl peptidase (spot
24) were also detected.
A series of spots showing no quantitative changes have also
been assigned. They include a 75-kDa heat shock protein, sub-
units of succinate dehydrogenase (complex II of the respiratory
chain), isocitrate dehydrogenase, succinyl-CoA synthetase, pyr-
roline-5 carboxylate reductase, prohibitin, and metaxin 2 (re-
sults not shown).
Perturbations within Pyruvate Dehydrogenase E1—Spots of
increased intensity in MERRF mitochondria are of particular
interest because they reveal active molecular events taking
place. This is mainly the case for PDH E1 subunits. The pyru-
vate dehydrogenase complex plays a central and strategic role
in the control and use of carbohydrates as source of oxidative
energy or as precursors of fatty acid biosynthesis (28). It is
formed of three enzymes, namely pyruvate dehydrogenase
(PDH E1), dihydrolipoyl trans-acetylase (PDH E2), and dihy-
drolipoyl dehydrogenase (PDH E3). PDH E1 is a heterotet-
ramer (22).
To understand differences in gel coordinates of spots 28 (43
kDa, pI 6.8) and 31 (42 kDa, pI 6.9), assigned as the same
protein PDH E1, the presence for post-translational modifi-
cations was investigated with particular attention to possible
phosphorylation. Indeed, negative charges of phosphates are
the best candidates to influence the pI of proteins. New data
bank searches performed with peptide masses, so far not in-
cluded in the assignments, combined with screening for phos-
phorylation on serine, threonine, or tyrosines fitted with the
possibility that PDH E1 extracted from spot 28 was phospho-
rylated at least at 4 positions (Ser-312, Ser-314, and two posi-
tions out of Ser-275, Thr-286, and Tyr-287) and that PDH E1
isoform extracted from spot 31 was phosphorylated at least at
5 different positions (Thr-35, Thr-124, Thr-126, Ser-130, and
Thr-139) (Table II). However, because phosphorylation lowers
the pI of a protein by about 0.2 units/phosphate group, protein
in spot 28, migrating at lower pI coordinates on the two-dimen-
sional gel than spot 31, is likely phosphorylated to a higher
extent than the protein in spot 31 (see location of spots in Fig.
1 and Fig. 5A). The definite degree of phosphorylation of each
subunit escapes MS analysis because of intrinsic limitations
of this technique (incomplete extraction of hydrophobic pep-
FIG. 1. Typical silver-stained two-dimensional gel electro-
pherogram of wild-type mitochondria from cybrid cells (R2-1A)
and location of protein spots that undergo quantitative changes
when compared with A8344G mutation-carrying mitochondria.
Mitochondria were purified from adherent cell lines and solubilized by
high concentration of denaturing agents and non-ionic detergents to
recover a large proportion of hydrophobic proteins. Proteins were sep-
arated by isoelectrofocusing (pH 5–8) followed by electrophoresis on a
10% polyacrylamide-SDS gel. Silver-stained gels were scanned and
quantified using PD-Quest software. Spots that display a greater than
2-fold decrease are indicated by open squares, and those displaying a
greater than 2-fold increase are shown by open circles. Spot numbers at
the sides of the gel are also relevant for later figures.
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tides from gels, non-detectable peptides) and remains so far
unknown.
Although in wild-type mitochondria intensities of spot 16
(subunit ) and spots 28  31 (subunits ) fit with a 1 to 1
stoichiometry, this is not the case in MERRF mitochondria
(Fig. 2). Thus, additional spots corresponding to alternative
isoforms of PDH E1 subunits were suspected to be present in
two-dimensional gels. To investigate this possibility further,
two-dimensional gels with healthy and MERRF mt proteins
were submitted to Western analysis in the presence of antibod-
ies directed against the PHD E1 (22) (Fig. 5, B and C). This
approach, which is much more sensitive than silver staining,
FIG. 2. Detailed quantitative view
of variations in spot intensity be-
tween wild-type and MERRF mu-
tation-carrying mitochondria. Only
spots exhibiting greater than 2-fold
changes in their quantity are reported. A,
histogram of the 19 spots with decreased
intensities in mutant mitochondria. Ra-
tios of intensities in wild-type/MERRF
mitochondria (wt/mt) are indicated. The
range of decrease in spot intensities var-
ies between 2.1- and 9.0-fold. B, histo-
gram of the 19 spots of increased intensi-
ties in MERRF mitochondria as compared
with wild-type mitochondria. Here ratios
of spot intensities in mutant over wild
type are given. The range of spot intensity
increment varies between 2.4- and 8.3-
fold. Bars for wild-type mitochondria are
indicated in white, and bars for mutant
samples are indicated in black. Mean val-
ues of 11 independent experiments with
corresponding standard errors are given.
FIG. 3. Representative result of MALDI-TOF mass spectrometric assignment. A, MALDI-TOF mass spectrum of in-gel tryptic peptides,
extracted from spot 31, identified as pyruvate dehydrogenase E1 subunit. Masses of the matching peptides allowing for identification are
indicated, and masses of phosphopeptides are underlined. B, linear representation of the polypeptide chain with matching peptides indicated in
gray. The protein sequence coverage was 42%. Amino acids forming the mt signal peptide are indicated at the N terminus of the sequence by a
zig-zag line. No matching peptides were found in this domain, in support to the absence of the targeting signal of the protein analyzed.
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indeed revealed the presence of additional spots aligned either
with spots 28–31 or with spot 16. MALDI-TOF analysis of one
spot in each of the two domains of interest in a corresponding
colloidal blue-stained gel (the only spots seen on blue gels,
namely spots 9 and 20), confirmed an additional subunit  (spot
20, with 39% sequence coverage) and subunit  (spot 9, with
52% sequence coverage), respectively, both with phosphoryla-
tion sites (not shown). Thus, the distribution of PDH E1 sub-
units into different isoforms is strongly perturbed in MERRF
mitochondria.
Comparison of Western blots showed not only large qualita-
tive but also significant quantitative differences (Fig. 5, B and
C). Complementary analysis by Western blotting on a one-
dimensional 10% polyacrylamide/SDS gel revealed that  and 
subunits are present in equimolar amounts in both wild-type
and mutated samples (not shown) and that the total quantity of
FIG. 4. Representative result of a nano-LC-MS-MS analysis. A, combined spectrum (retention time from 15 to 50 min) of in-gel tryptic
digested peptides of spot 22, identified as the mt 28 S ribosomal protein MRP-S22. Masses of peptides allowing identification are indicated. B,
linear representation of the polypeptide chain with sequences of matching peptides. Total sequence coverage was 16%. No match for the mt target
signal (zigzag line) was found.
TABLE I
Assignment of proteins in spots undergoing quantitative changes
Spots are listed according to numbers shown in Fig. 1. Two classes of spots are distinguished: 2, spots with decreased intensities in MERRF
samples as compared with wild-type mitochondria;1, spots with increased intensities in mutant samples. Protein assignment was done by mass
spectrometric approaches. Variations in spot intensities are expressed as ratios of either wild-type/mutant (wt/mt) or mt/wt. Names of protein,
SwissProt data bank accession numbers, subcellular localization, theoretical molecular weights or isoelectric points (calculated for the mature
forms of the proteins), and % of mass coverage for peptides allowing for assignment, are indicated. Loc., subcellular localization; Mt, mitochondria;
C, cytosol; L, lysosome; Px, peroxisome.
Experimental Data bank exploration
Spot
Number Ratio
Molecular
mass/pI Protein name
Accession
no. Loc.
Molecular
mass pI
Mass
coverage
2 Decrease in intensity
kDa Da
35 2.7 12/6.05 NADH/ubiquinone oxidoreductase, 3-kDa subunit Q16718 Mt 13.327 5.77 68
46 2.7 25/6.2 NADH/ubiquinone oxidoreductase, 24-kDa subunit P19404 Mt 23.760 5.71 45
67 3.6 78/5.6 NADH/ubiquinone oxidoreductase, 75-kDa subunit P28331 Mt 77.053 5.33 37
68 2.6 78/5.7 NADH/ubiquinone oxidoreductase, 75-kDa subunit P28331 Mt 77.053 5.33 28
69 3.3 78/5.8 NADH/ubiquinone oxidoreductase, 75-kDa subunit P28331 Mt 77.053 5.33 52
42 6.1 16/7.15 Cytochrome c oxidoreductase, subunit Vb P10606 Mt 10.613 6.74 34
41 9.0 13/7.2 Cytochrome c oxidoreductase, subunit VIa Q02221 Mt 9.750 6.97 62
34 7.8 10/6.4 Cytochrome c oxidoreductase, subunit VIb P14854 Mt 10.061 6.79 65
61 2.8 44/6.7 Ornithine aminotransferase P04181 Mt 44.808 5.72 28
50 3.1 33/6.8 Enoyl CoA hydratase Q08426 Px 35.816 8.07 22
51 2.1 34/6.9 Enoyl CoA hydratase Q08426 Px 35.816 8.07 21
1 Increase in intensity
28 8.3 43/6.8 Pyruvate dehydrogenase subunit E1 P08559 Mt 40.229 6.51 28
31 3.4 41/6.9 Pyruvate dehydrogenase subunit E1 P08559 Mt 40.229 6.51 42
16 2.4 35/6.0 Pyruvate dehydrogenase subunit E1 P11177 Mt 35.890 5.38 31
22 5.8 38/6.8 Mt ribosomal protein 28 S subunit S22 P82650 Mt 41.280 7.70 31
30 7.5 47/6.8 Elongation factor-1 P26641 C 50.119 6.25 28
15 4.8 38/5.85 -Actin P02570 C 41.053 5.56 44
13 4.0 35/5.8 -Actin guanine nucleotide-binding protein
subunit 3
P02570 C 41.053 5.56 44
P16520 C 37.221 5.39 37
27 3.9 43/6.7 Septin 2 Q15019 C 41.487 6.15 57
24 4.8 43/6.05 Lysosomal tripeptidyl peptidase O14773 L 39.790 5.61 35
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PDH E1 subunits increased about 2-fold in MERRF samples
compared with wild type.
PDH E1 activity is under control of phosphorylation/dephos-
phorylation at well defined sites of E1 (28). Both forms (phos-
phorylated and non-phosphorylated) co-exist in a given cell and
allow for sensitive regulation by shifting their balance. It is
possible to measure basal activity, representative of the non-
phosphorylated population of enzyme, and total activity subse-
quent to dephosphorylation by calcium and magnesium activa-
tion of phosphatases (24). Neither basal nor total activities are
significantly different in wild-type and MERRF mitochondria
in the presence of pyruvate as substrate (Table III).
DISCUSSION
Comparative proteomics, combining high resolution of pro-
teins with mass spectrometry techniques for rapid assignment,
have presently been recognized as a powerful tool for the in-
vestigation of a number of human diseases (e.g. Refs 17, 29, and
30) including mt disorders (31–33). Further, proteomic maps of
mammalian mitochondria become progressively presented in
the case of human placenta (34) and rat liver (35).
Couples of cybrid cell lines form a valuable model system to
investigate biochemical and molecular consequences of a mu-
tation in the mt genome because they possess the same nuclear
background and differ by a single point mutation (36). Osteo-
sarcoma-derived cybrids were used previously to study the
physiological, biochemical, and molecular effects of the A8344G
mutations in the mt tRNALys gene which is correlated to the
maternally inherited MERRF syndrome (22). MERRF cells
have a decreased growth rate, lower oxygen consumption, and
reduced cytochrome c oxidase activity and ATP synthesis, so
that the cell undergoes a severe energy deficit (25, 27). At the
molecular level, mt protein synthesis is severely impaired, and
the steady-state level of the 13 mitochondria encoded proteins
is decreased according to their lysine content (26). Initial com-
parative proteomics on these cybrid cell lines revealed that at
least two nuclear encoded proteins of mt location (COX sub-
units Va and VIb) have severely decreased steady-state levels
(21). The fate of the 13 mitochondria-encoded proteins cannot
be explored by two-dimensional gel analysis due to their hy-
drophobicity and/or their extreme pI (34). The present work,
exploring silver-stained gels on a computer-assisted basis, en-
larges the knowledge of the fate of about 800 proteins contained
in MERRF mitochondria compared with wild type.
Variations in Steady-state Levels of Non-mitochondrial Pro-
teins—Assignment of regulated spots as non-mitochondrial
proteins was not unexpected because mitochondria were not
purified to completion. Several of these proteins are eliminated
when mitochondria are further purified on a metrizamide gra-
dient before their analysis on two-dimensional gels (results not
shown). However, the very low yield of this purification proce-
dure prevented its systematic use in the present work. The fact
that certain contaminants systematically co-purify with al-
TABLE III
Activity of pyruvate dehydrogenase in wild-type and
MERRF mutation containing mitochondria (pmol/min/mg
of total cellular proteins)
Each activity was measured in triplicate on cell extracts pooled from
three cell cultures.
Wild type MERRF
Basal activity 187 141
Total activity 641 673
FIG. 5. Detection of pyruvate dehydrogenase E1 subunit iso-
forms by Western blotting. A, detail of a silver-stained two-dimen-
sional gel of MERRF mutation-carrying mitochondria with spots as-
signed by MALDI-TOF as PDH E1 subunits  (spots 28 and 31) and
subunit  (spot 16) indicated. B and C, Western blots of the same
domain of non-stained two-dimensional gels performed with antibodies
directed against PDH E1 holoenzyme. B corresponds to a wild-type mt
sample, and C corresponds to a MERRF mitochondria. Immunoreactiv-
ity for  subunit resulted mainly in one major spot in wt (spot 9) and
four spots in mutant samples. Immunoreactivity for  subunits resulted
in a major spot (20) in wt, and to a large row of spots of the same
molecular weight (about 40 kDa) in the mutant sample. Within all these
newly detected spots, two were detectable on colloidal blue-stained
two-dimensional gels (9 and 20) and have been further analyzed.
MALDI-TOF measurements support the assignment of phosphorylated
isoforms.
TABLE II
Phosphorylated peptides in isoforms of pyruvate dehydrogenase E1 subunits
Masses of phosphorylated peptides are shown according to experimental data by MALDI-TOF (Mr observed), to data bank derived values (Mr
expected), and to “normalized” data (Mr calculated). Phosphorylation sites are underlined in peptide sequences, and the number of phosphoryla-
tions is indicated. The peptides reported here probably correspond only to a subset of phosphorylation sites. Tryptic peptides corresponding to
regulatory sites already reported for the enzyme are not detected by MALDI-TOF MS, probably due to their high hydrophobicity and acidic pI.
Mr observed Mr expected Mr calculated Amino acids Peptide sequence No. of phosphates
Spot 28 (E1)
1307.63 1306.62 1306.56 312-321 SKSDPIMLLK 2
1768.77 1767.76 1767.77 275-288 SGKGPILMELQTYR 2
Spot 31 (E1)
1477.82 1476.81 1476.66 29-40 NFANDATFEIKK 1
1673.97 1672.96 1672.79 128-141 GLSVREILAELTGR 2
1688.73 1687.72 1687.67 120-132 AHGFTFTRGLSVR 3
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tered proportions in MERRF mt samples suggests that their
detection is significant and may have a link with the patholog-
ical status of the whole cell. They may be linked to biochemical
perturbations (e.g. acidification of the cytosol, change in ionic
concentrations, and variation in mt membrane potential (37–
39)) leading to alterations in physicochemical properties of
these proteins. Some cytosolic proteins may become bound
more or less tightly to the outer mt membrane. Alternatively,
detection of quantitative changes in cytosolic proteins may
reflect true molecular long range effects of the mt tRNA gene
mutation such as overexpression or down-regulation of cytoso-
lic proteins. This awaits further experimentation.
Decrease in Nuclear Encoded Subunits of Respiratory Chain
Complexes—Among the 38 protein spots found to be quantita-
tively affected, 6 were assigned as nuclear encoded subunits of
the respiratory chain complexes, i.e. subunits of complex I and
of complex IV. Interestingly, those affected subunits from the
same complex were decreased by the same factor, i.e. about
7.5-fold for complex IV subunits and about 3-fold for complex I
subunits.
Complexes of the mt respiratory chain (with the exception of
complex II) are composed of both mt and nuclear encoded
subunits assembled into functional entities in the inner mt
membrane. The stoichiometric assembly of these complexes
necessarily depends on a well organized nucleo-mitochondrial
communication allowing for fine-tuning of the expression levels
of the corresponding genes in both genomes (40, 41). Although
a strong decrease in steady-state levels of any nuclear encoded
mt protein could result from different molecular regulatory
events taking place either at the gene expression level (tran-
scription and translation) or at the mt import level, it is likely,
as suggested earlier (21), that the decreases observed here for
nuclear respiratory chain subunits are the direct consequence
of their degradation. Indeed, because mtDNA encoded subunits
are synthesized at a lower rate, as a direct consequence of the
tRNA mutation (26), their nuclear partners likely remain non-
assembled and are therefore degraded. Such a situation has
been demonstrated for COX nuclear encoded subunits in cell
lines deprived of mtDNA or where mt translation has been
inhibited (42–46). Interestingly, subunits from complex II (suc-
cinate dehydrogenase), which are all nuclear encoded and are
thus not linked to mt translation, were not found to be regu-
lated in the present work.
The five mt respiratory chain complexes are formed from 83
different subunits, of which only 13 are of mt origin. Only 6 of
the 70 nuclear encoded subunits were found to be down-regu-
lated here. The fate of the 64 remaining subunits is thus
uncertain. Calculation of theoretical molecular weight and pI
values for each subunit revealed that at least 22 of them should
have coordinates within the two-dimensional gels studied in
the present work. Their absence could reflect either their mem-
brane location and thus difficulty to be extracted (in the x-ray
structure of complex IV (47), the three subunits detected here
are located on the matrix and intermembrane surfaces of the
enzyme rather than within the membrane), their presence
within spots which could not be assigned, or that they are not
regulated or are regulated below a 2-fold factor.
Variation in Steady-state Levels of Proteins Involved in Mi-
tochondrial Translation—Due to impairment of mt translation
by mutation A8344G in the tRNALys gene, effects on proteins
involved in the translational machinery may be affected. Only
one ribosomal protein, MRP-S22, was found in increased quan-
tity in MERRF mitochondria (about 6-fold). The regulation of
the steady-state level of only one of the 80 proteins which
form the mt ribosome is surprising. Protein MRP-S22 belongs
to a new class of ribosomal proteins, specific to mammalian
ribosomes (48, 49). This protein may well have an additional
alternative function, so far unknown, as observed for other
newly discovered mt proteins. MRP-S29 is a death-associated
protein involved in apoptosis (50), and MRP-S31 is associated
with type 1 diabetes (51). To explore further possible variations
in proteins belonging to the mt translational machinery, West-
ern blotting with antibodies directed against human lysyl-
tRNA synthetase (the enzyme which catalyzes aminoacylation
of tRNALys, the tRNA bearing the MERRF mutation investi-
gated here) and against mt translation elongation factor Tu
was performed. No significant changes in the steady-state lev-
els of these two particular proteins were found (not shown).
Variations in Steady-state Amounts of Metabolic Enzymes—
Two metabolic enzymes were found to be affected in MERRF
cells. Mitochondrial ornithine aminotransferase decreased, and
pyruvate dehydrogenase subunits E1 and E1 increased. Or-
nithine aminotransferase participates in amino acid metabo-
lism, catalyzing inter-conversion of ornithine and glutamate.
The contribution of the decrease of ornithine aminotransferase
to the pathological status of the cybrid cells remains unclear.
However, reduced activity of the respiratory chain correlates
directly with reduced activity of the Krebs cycle, which in turn
is linked via -ketoglutarate to glutamate. Interestingly, a
reduced activity of this enzyme was observed previously in the
brains of Huntington’s disease-affected patients. Huntington’s
disease is associated with the deficiency of the neurotransmit-
ter glutamate and of mt oxidative phosphorylation (52).
The pyruvate dehydrogenase complex converts pyruvate into
acetyl-CoA and has thus a central role in energy metabolism.
Comparative proteomics associated with Western analysis re-
vealed that (i) the total amount of PDH E1 subunits increased
about 2-fold in MERRF mitochondria, and (ii) both subunits 
and  of this enzyme are distributed over a series of isoforms in
the wild-type sample, but this distribution is wider in the
mutated sample. MALDI-TOF assignments are in favor of a
variation in the number and distribution of phosphorylation
sites as post-translational modifications in the different iso-
forms. The detected phosphorylation sites differ from those
involved in regulation of PDH E1 activity (53) in agreement
with maintenance of the same enzymatic PDH activity in both
wild-type and MERRF cell lines. Whereas full understanding of
biochemical and molecular perturbations of the PDH complex
and their relationships with the presence of the MERRF mu-
tation in the mt genome awaits further experiments, it is
important to notice that the results of the present investigation
do not preclude on the activity of the PDH complex in vivo.
Indeed, in addition to phosphorylation/dephosphorylation at
three specific sites, the activity of the complex can be alloster-
ically regulated by NADH and acetyl-CoA (28). Both com-
pounds accumulate in mitochondria as a consequence of respi-
ratory deficiency. As an outcome of the present data, it is
tempting to speculate that accumulation of the enzyme may
represent a compensatory mechanism by the cell to overcome
the energetic deficiency but that parallel activation of kinase(s)
hinders effective changes in activity. Interestingly, a case of
up-regulation of the amounts of PDH E1 proteins has been
reported recently for butyrate-treated human colon cancer cells
(54).
Expectation for Further Variations—Comparative proteom-
ics allowed for an enlarged view of quantitative and qualitative
changes in about 800 protein spots observed on two-dimen-
sional gels from wild-type mitochondria and mitochondria con-
taining a single point mutation in a tRNA gene. The present
analysis revealed 38 affected spots, of which 20 could be as-
signed, and about 760 unaffected spots. As a major outcome,
mitochondria with mutation A8344G in the tRNALys gene show
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significant perturbations in the steady-state amounts of pro-
teins involved in translation (MRP-S22), respiration (respira-
tory chain subunits), and carbohydrate and amino acid metab-
olism (PDH, ornithine aminotransferase). Also a series of
proteins of cytosolic location were reproducibly found to be
affected (either increased or decreased). These results demon-
strate that the presence of a single point mutation in an mt
tRNA gene not only affects mt translation but also several
categories of nuclear encoded proteins, both of mt and cytosolic
location. Possible links between these proteins and the muta-
tion in an mt tRNA gene are schematized in Fig. 6.
However, it must also be stated that the number of changes
observed in the MERRF cell line is rather limited in regard of
the severity of the physiological and energetic perturbations
taking place. The observed quantitative variations reveal only
the strongest intensity changes taking place (variations of 2.1–
9-fold) and certainly correspond only to a subset of molecules
that undergo perturbations in the disease-related cells. Sensi-
tive quantitative variations within a 2-fold range may be sig-
nificant biologically and relevant. They escape the present
analysis, however, due to limited accuracy and reproducibility.
As discussed above, the fate of many respiratory chain complex
subunits escaped analysis. Furthermore, changes in enzymes
involved in the glycolytic pathway or those involved in other
energy-related pathways would be expected to be affected.
Thus, it is likely that only the “tip of the iceberg,” in regard to
regulatory events taking place in mitochondria, was detected
so far. Many proteins may well have escaped the present anal-
ysis due to technical limitations including limited sensitivity of
silver-stained gels for poorly represented proteins, analysis of
basic and hydrophobic proteins, and difficulty in assignment of
some proteins (especially those of low molecular weight). Re-
cent developments in proteomic technology (e.g. Refs. 55–59)
should allow some of these difficulties to be overcome and lead
to more precise comparative analyses. Also comparison of the
same quantity of proteins in either wild-type or mutation-
carrying mitochondria, as done here, does not exclude the pos-
sibility of larger cellular changes such as regulation in the
biogenesis of mitochondria per cell, for example. The two typ-
ical mt enzymatic activities measured for both cell lines (citrate
synthase and pyruvate dehydrogenase) argue, however,
against this possibility. Finally, one should keep in mind that
regulation of enzymatic activities does not necessarily involve
quantitative variations of their steady-state levels but can be
controlled by other biochemical and biophysical means.
Perspectives—The present work used osteosarcoma cybrid
cell lines as a model system to explore long range effects of a
single mt tRNA gene mutation on the global mt proteome,
outside the frame of mt translation. The initial results reported
here clearly show the occurrence of such events and open new
questions on the molecular mechanisms linking all events.
Indeed, it remains to be explored if the observed effects are
specifically related to the A8344G mutation or if this is general
for other tRNA mutations. Initial studies on cybrid cell lines
carrying mutation A3243G in the tRNALeu(UUR) gene repre-
senting a model system of the Mitochondrial Epilepsy, Lactic
Acidosis, and Stroke-like episode syndrome already revealed a
decrease in two COX subunits, as is the case with the MERRF
mutation (21). Furthermore, systematic analysis of cell lines
with different nuclear backgrounds for the same tRNA muta-
tion (e.g. mutation 8344 in myeloblasts or fibroblasts) should
allow one to discriminate between mutation-specific and non-
specific perturbations and to decipher the contribution of the
nuclear background. The present proteomic investigation,
which so far uncovered several unsuspected new players that
participate in the disease status of the cell, opens new territory
for molecular and biochemical investigation. Their exploration
will shed light on the intricate mechanistic pathways linking a
FIG. 6. Schematic representation of the most dramatic perturbations observed by comparative proteomics on two-dimensional
silver-stained gels in mitochondria harboring tRNALys gene mutation A3243G. Mt and nuclear gene expression machinery are considered,
and their convergence at the level of respiratory chain complexes is illustrated. Major relevant energetic metabolic pathways and their connections
to the respiratory chain are indicated. Decreases and increases in protein spots as seen on two-dimensional gels are indicated by arrows. Decreases
in the 13 mt encoded subunits of the respiratory chain complexes as described (e.g. Ref. 26) were not observed on two-dimensional gels due to their
hydrophobicity.
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single point mutation in the mt tRNA gene to phenotypic ex-
pression of mitochondrial diseases.
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